(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
HEALTHCARE:  Michael Rea, CEO of Rx Savings Solutions, to discuss the wide gap in Mylan's EpiPen drug pricing between the UK ($69) and the US ($600.)

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox.

GUEST:
HEALTHCARE: Michael Rea, CEO of Rx Savings Solutions, to discuss the wide gap in Mylan's EpiPen drug pricing between the UK ($69) and the US ($600.)

Listen for investment news and in-depth company research. 

Hosts Paul Sweeney and Scarlet Fu harness the power of Bloomberg Intelligence to analyze investments on Wall Street. Watch Bloomberg Intelligence LIVE on YouTube, weekdays from 10AM to 12PM ET: http://bit.ly/3vTiACF.

Listen for investment news and in-depth company research. Hosts Paul Sweeney and Scarlet Fu harness the power of Bloomberg Intelligence to analyze investments on Wall Street. Watch Bloomberg Intelligence LIVE on YouTube, weekdays from 10AM to 12PM ET: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

Rx Savings’ Rea on Wide Gaps in EpiPen Drug Pricing (Audio)

Rx Savings' Rea on Wide Gaps in EpiPen Drug Pricing (Audio)

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/2e102472-824e-497c-9ee1-ae3c0085e7f6/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Scarlet Fu & Stacey Vanek Smith

- Mark Gurman, Bloomberg News Managing Editor for Global Consumer Tech, discusses John Ternus taking the reins as Apple CEO on September 1st. John Ternus won’t have much time before the company begins its annual fall product rollouts. This year the lineup will include an unusually ambitious slate of devices he’s been teasing for months internally, including the first foldable iPhone and a smart display that can recognize who’s speaking and tailor content to them. Former CEO Tim Cook told employees he will miss the role of chief executive officer but has "enormous comfort" in the leadership of his replacement, John Ternus.

-Ed Ludlow, Bloomberg Tech Anchor, discusses Anthropic agreeing to a $35 billion computing deal with Lambda, a cloud provider backed by Nvidia Corp. The deal is part of an effort to quickly expand Anthropic's AI capacity, and involves a Texas data center being developed by Hut 8. He also talks about John Ternus taking the reins as Apple CEO on September 1st.   

-Matt Henriksson, Bloomberg Intelligence Senior Medtech Analyst, discusses Medtronic earnings. According to Bloomberg Intelligence: Medtronic beating estimates and raising guidance point to expanding market share in its cardiovascular franchise, which should aid the company's pivot to its robotic strategy. Medtronic raised its outlook for organic sales growth to 7.25-7.75% from 6.75-7.25%, thanks to a 88% gain in fiscal 1Q for Cardiac Ablation Solutions, which houses pulsed field ablation tech, and an increase in the low-20% range for the Micra leadless pacemaker.

-Gautam Mukunda, Lecturer at Yale School of Management and Bloomberg Opinion contributor, discusses his column: “Big Tech Is Incapable of Solving Its Own Problem.” Bill Gates published an essay saying he would slow the development of artificial intelligence if he could, and elaborated that people who understand AI are "very worried" but few are raising issues in public. A bipartisan coalition of attorneys general announced a proposed settlement with Meta Platforms Inc. that obligates the company to put restrictions on how children use its platforms, including a two-hour default daily limit and a block from midnight to 6 a.m. The tech industry's lack of self-regulation and prioritization of profit over safety has led to public opposition, with many Americans saying they don't trust AI leaders and opposing data center construction.

 

 

Watch Paul and Scarlet LIVE every day on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>. Bloomberg Intelligence hosted by Scarlet Fu &amp; Stacey Vanek Smith - Mark Gurman, Bloomberg News Managing Editor for Global Consumer Tech, discusses John Ternus taking the reins as Apple CEO on September 1st. John Ternus won&rsquo;t have much time before the company begins its annual fall product rollouts. This year the lineup will include an unusually ambitious slate of devices he&rsquo;s been teasing for months internally, including the first foldable iPhone and a smart display that can recognize who&rsquo;s speaking and tailor content to them. Former CEO Tim Cook told employees he will miss the role of chief executive officer but has "enormous comfort" in the leadership of his replacement, John Ternus. -Ed Ludlow, Bloomberg Tech Anchor, discusses Anthropic agreeing to a $35 billion computing deal with Lambda, a cloud provider backed by Nvidia Corp. The deal is part of an effort to quickly expand Anthropic's AI capacity, and involves a Texas data center being developed by Hut 8. He also talks about John Ternus taking the reins as Apple CEO on September 1st.&nbsp;&nbsp; -Matt Henriksson, Bloomberg Intelligence Senior Medtech Analyst, discusses Medtronic earnings. According to Bloomberg Intelligence: Medtronic beating estimates and raising guidance point to expanding market share in its cardiovascular franchise, which should aid the company's pivot to its robotic strategy. Medtronic raised its outlook for organic sales growth to 7.25-7.75% from 6.75-7.25%, thanks to a 88% gain in fiscal 1Q for Cardiac Ablation Solutions, which houses pulsed field ablation tech, and an increase in the low-20% range for the Micra leadless pacemaker. -Gautam Mukunda, Lecturer at Yale School of Management and Bloomberg Opinion contributor, discusses his column: &ldquo;Big Tech Is Incapable of Solving Its Own Problem.&rdquo; Bill Gates published an essay saying he would slow the development of artificial intelligence if he could, and elaborated that people who understand AI are "very worried" but few are raising issues in public. A bipartisan coalition of attorneys general announced a proposed settlement with Meta Platforms Inc. that obligates the company to put restrictions on how children use its platforms, including a two-hour default daily limit and a block from midnight to 6 a.m. The tech industry's lack of self-regulation and prioritization of profit over safety has led to public opposition, with many Americans saying they don't trust AI leaders and opposing data center construction.
&nbsp;
&nbsp;

Apple’s Ternus Takes Reins as CEO With AI a Priority 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d5126a66-7226-41e1-aed3-b4b801185a04/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu

-Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, discusses Nvidia investing $3.5 billion in MediaTek to deepen collaboration with the Taiwanese chipmaker. The investment will see MediaTek using Nvidia's NVLink Fusion and NVHBM technology to help components communicate more seamlessly in data centers. The agreement is part of Nvidia's effort to ensure the future of artificial intelligence is built around its hardware platform and standards.

-Bailey Lipschultz, Bloomberg News Senior Equities Reporter, discusses Anthropic’s future IPO. Anthropic PBC’s IPO is expected to raise as much as SpaceX’s record $86.2 billion debut and is casting a long shadow over companies’ US listing plans. Some firms are finding it hard to get the attention of investors with the prospect of an Anthropic IPO imminent, and companies may decide to list before or after Anthropic to avoid competition.

-Michelle Cortez, Bloomberg Senior Editor for Global Business, discusses Eli Lilly plans to buy Merida Biosciences for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases. Merida is developing products that target auto-antibodies tied to diseases, including MER511, which is in early testing for Graves’ disease and thyroid eye disease. The deal is part of Lilly’s strategy to invest in technologies that can transform the treatment of diseases beyond obesity, with the company having announced more than $20 billion in deals so far in 2026.

- Matthew Palazola, Bloomberg Intelligence, Senior Analyst, P&C Insurance, discusses KKR being set to reap a $3.3 billion windfall from its deal to sell USI Insurance Services to Aon Plc for $17 billion. The transaction will generate about $2 billion of adjusted net income for the private equity giant, according to a statement. The sale is expected to generate a 3.4 times return on KKR’s balance-sheet capital invested, and will help expand Aon’s middle-market business.

Watch Paul and Scarlet LIVE every day on YouTube:&nbsp;<a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>. Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu -Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, discusses Nvidia investing $3.5 billion in MediaTek to deepen collaboration with the Taiwanese chipmaker. The investment will see MediaTek using Nvidia's NVLink Fusion and NVHBM technology to help components communicate more seamlessly in data centers. The agreement is part of Nvidia's effort to ensure the future of artificial intelligence is built around its hardware platform and standards. -Bailey Lipschultz, Bloomberg News Senior Equities Reporter, discusses Anthropic&rsquo;s future IPO. Anthropic PBC&rsquo;s IPO is expected to raise as much as SpaceX&rsquo;s record $86.2 billion debut and is casting a long shadow over companies&rsquo; US listing plans. Some firms are finding it hard to get the attention of investors with the prospect of an Anthropic IPO imminent, and companies may decide to list before or after Anthropic to avoid competition. -Michelle Cortez, Bloomberg Senior Editor for Global Business, discusses Eli Lilly plans to buy Merida Biosciences for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases. Merida is developing products that target auto-antibodies tied to diseases, including MER511, which is in early testing for Graves&rsquo; disease and thyroid eye disease. The deal is part of Lilly&rsquo;s strategy to invest in technologies that can transform the treatment of diseases beyond obesity, with the company having announced more than $20 billion in deals so far in 2026. - Matthew Palazola, Bloomberg Intelligence, Senior Analyst, P&amp;C Insurance, discusses KKR being set to reap a $3.3 billion windfall from its deal to sell USI Insurance Services to Aon Plc for $17 billion. The transaction will generate about $2 billion of adjusted net income for the private equity giant, according to a statement. The sale is expected to generate a 3.4 times return on KKR&rsquo;s balance-sheet capital invested, and will help expand Aon&rsquo;s middle-market business.

Nvidia to Invest $3.5 Billion in Chipmaker MediaTek 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/60ceb4ea-dc6b-4e8f-a3e8-b4b7010f3a95/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Judy Lagrou

*Guest reaction to Fed Chair Kevin Warsh’s speech from Jackson Hole*
Guests: Tom Orlik, Chief Economist for Bloomberg Economics & Tom Keene, Bloomberg Surveillance Co-Anchor
-Federal Reserve Chairman Kevin Warsh warned inflation isn’t meaningfully slowing and said policymakers must be confident that it is, otherwise the central bank has “work to do.”
Warsh reiterated that policymakers will return inflation to their 2% goal, which he said is a firm and fixed target, and that financial conditions are not currently restrictive.
Warsh said interest rates are the Fed’s “predominant tool” for achieving its mandate, but stopped short of signaling he would support an interest-rate hike when Fed officials gather in September.

Also on this podcast:
Nic Querolo, Bloomberg Municipal Finance Reporter, discusses the latest on the munis bond market.
Investors in the high-yield municipal bond market are being picky and have shied away from some recent offerings, such as one from QCF/I, Inc.
Higher absolute yields and tighter spreads between investment grade and riskier debt have given bond buyers fewer reasons to consider deals further down the credit spectrum.
High-yield defaults have been in line with historical levels this year, with 33 first-time defaults totaling $2.81 billion, according to Municipal Market Analytics.

 

Watch Paul and Scarlet LIVE every day on YouTube:&nbsp;<a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>. Bloomberg Intelligence hosted by Paul Sweeney and Judy Lagrou *Guest reaction to Fed Chair Kevin Warsh&rsquo;s speech from Jackson Hole* Guests: Tom Orlik, Chief Economist for Bloomberg Economics &amp; Tom Keene, Bloomberg Surveillance Co-Anchor -Federal Reserve Chairman Kevin Warsh warned inflation isn&rsquo;t meaningfully slowing and said policymakers must be confident that it is, otherwise the central bank has &ldquo;work to do.&rdquo; Warsh reiterated that policymakers will return inflation to their 2% goal, which he said is a firm and fixed target, and that financial conditions are not currently restrictive. Warsh said interest rates are the Fed&rsquo;s &ldquo;predominant tool&rdquo; for achieving its mandate, but stopped short of signaling he would support an interest-rate hike when Fed officials gather in September. Also on this podcast: Nic Querolo, Bloomberg Municipal Finance Reporter, discusses the latest on the munis bond market. Investors in the high-yield municipal bond market are being picky and have shied away from some recent offerings, such as one from QCF/I, Inc. Higher absolute yields and tighter spreads between investment grade and riskier debt have given bond buyers fewer reasons to consider deals further down the credit spectrum. High-yield defaults have been in line with historical levels this year, with 33 first-time defaults totaling $2.81 billion, according to Municipal Market Analytics.
&nbsp;

Warsh Says Inflation Isn’t Slowing, Vows to Reach 2% Target 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d2d4a5e3-0311-4125-89f0-b4b40112bcaa/transcript

Rx Savings' Rea on Wide Gaps in EpiPen Drug Pricing (Audio)

In 1 playlist(s)

Bloomberg Intelligence

Social links

Follow podcast

Recent clips